Correction of venlafaxine- and duloxetine-induced transaminase elevations with desvenlafaxine in a patient with Gilbert's syndrome

CNS Spectrums

Volumn 15, Issue 1, 2010, Pages 53-55

  Feinberg, S Shalom ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2D6; DESVENLAFAXINE; DULOXETINE; SERTRALINE; TERAZOSIN; VENLAFAXINE; AMINOACYLTRANSFERASE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE; THIOPHENE DERIVATIVE; TRANSAMIDASES;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANHEDONIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEAR; FLU LIKE SYNDROME; GILBERT DISEASE; HUMAN; MALE; NAUSEA; PANIC; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCREENING TEST; SEDATION; SIDE EFFECT; SOCIAL ASPECT; SOCIAL PHOBIA; SWEATING; SYMPTOMATOLOGY; METABOLISM;

ADULT; AMINOACYLTRANSFERASES; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; GILBERT DISEASE; HUMANS; MALE; THIOPHENES;

EID: 77951921065     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900000304     Document Type: Article

References (16)

1. Pristiq vs. Effexor. The Carlat Psychiatry Report. 2008; 6:1-6.
2. Desvenlafaxine for Depression. The Medical Letter. 2008; 50:37-39.
3. Desvenlafaxine (Pristiq). Biological Therapies in Psychiatry. 2008; 31:21-22.
4. Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008; 36:2484-491.
5. Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol. 2001;41:443-451.
6. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol. 2003; 38:107-117.
7. Burchell B, Hume R. Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol. 1999;14:960-966.
8. Desanty KP, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother. 2007;41:1201-1211.
9. Dear Healthcare Professional Letter. Cymbalta (duloxetine hydrochloride) Indianapolis, IN: Eli Lilly and Co., October 2005. Available at: www.fda.gov/downloads/Safety/MedwaTCH/safetyinformation/safety/alertsforhumanmedicalproducts/UCM164428.pdf. Accessed August 27, 2009.
10. Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2008 (Revised).
11. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996; 16(3 suppl 2):54S-61S.
12. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc. 2008.
13. Clayton AH, Kornstein SG, Rosas G, et al. An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Comparedwith Placebo in the Treatmentof Major Depressive Disorder. CNS Spectr. 2009;14:183-195.
14. Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract. 2008;14:368-378.
15. Bleibel W, Kim S, D'Silva K, Lemmer ER. Drug Induced Liver Injury: review Article. Dig Dis Sci. 2007;52:2463-2471.
16. Schatzberg AF, Nemeroff CB, eds. Textbook of Psychopharmacology. Third edition. Washington, DC: American Psychiatric Publishing; 2004.